Stay updated on Pembrolizumab and Radiotherapy in Melanoma: Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Radiotherapy in Melanoma: Clinical Trial page.

Latest updates to the Pembrolizumab and Radiotherapy in Melanoma: Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedMelanoma and MedlinePlus Genetics were added to the related topics section of the study page, enhancing disease context and links to patient resources.SummaryDifference0.2%

- Check20 days agoChange DetectedThe study record reflects an update to outcome-measure definitions and timelines (e.g., RECIST response assessment at 12 weeks and follow-up, PFS/OS timepoints, and safety/tolerability reporting windows) along with corresponding eligibility-criteria text describing required health status and reproductive-contraception requirements. It also updates the record’s “results posted”/last-updated metadata associated with the April 2026 posting.SummaryDifference3%

- Check27 days agoChange DetectedRevision update applied to the page, replacing the previous revision with a newer version.SummaryDifference0.1%

- Check34 days agoChange DetectedRemoved 'Melanoma' and 'MedlinePlus Genetics' from the related topics section.SummaryDifference0.2%

- Check42 days agoChange DetectedMedlinePlus Genetics is now listed in related topics, alongside Melanoma.SummaryDifference0.2%

- Check56 days agoChange DetectedAdded Revision: v3.5.0 and removed Revision: v3.4.3.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab and Radiotherapy in Melanoma: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Radiotherapy in Melanoma: Clinical Trial page.